Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes
References (20)
The formation, isolation and identification of DNA adducts produced by anticancer platinum complexes
Pharmacol. Ther.
(1987)- et al.
Enantiomeric cisplatin analogues: an investigation on their activity towards tumors in mice
Inorg. Chim. Acta
(1984) - et al.
The synthesis and antitumor properties of a series of water soluble carboxylato(1,2-diaminecyclohexane)platinum(II) complexes
Inorg. Chim. Acta
(1985) - et al.
Mono- and bifunctional binding of cis-diamminedichloroplatinum(II) to dinucleotides
Chem.-Biol. Interact.
(1987) Glutathione-mediated activation of anticancer platinum(IV) complexes
Biochem. Pharmacol.
(1987)Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II)
Biochemistry
(1983)Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA
Biochemistry
(1986)- et al.
Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia
Cancer Res.
(1977) - et al.
Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form
J. Med. Chem.
(1978) - et al.
Antitumor activity of platinum(II) complexes of 1,2-diaminocyclohexane isomers
Gann
(1980)
Cited by (99)
Oxaliplatin and its derivatives – An overview
2023, Coordination Chemistry ReviewsPlatinum iodido complexes: A comprehensive overview of anticancer activity and mechanisms of action
2019, Coordination Chemistry ReviewsCitation Excerpt :Oxaliplatin was approved by FDA in 2002 and it is, in combination with 5-fluorouracil and leucovorin, used for the treatment of colorectal cancer naturally resistant to cisplatin. Mechanism of action of the platinum-based drugs is based on the intracellular hydrolysis (aquation) resulting in the displacement of the Cl−/cbdc/ox ligands (leaving groups) and formation of the positively charged aqua/hydroxido-species, capable to covalently attack the target DNA molecule, while the N-donor carrier ligands (NH3 or RRdach) remain intact during the described mechanistic processes [5–10]. Although the clinical success of cisplatin and its analogues is unprecedented, application of these drugs is connected with serious side effects (e.g., myelosuppression, nephrotoxicity or neurotoxicity) and with problems of both intrinsic and acquired resistance connected with the induction of protective cellular processes, including the cell accumulation and efflux, or Pt–DNA adduct recognition and repair [6,11–13].
Cytotoxic platinum coordination compounds. DNA binding agents
2017, Coordination Chemistry ReviewsPlatinum complexes containing adenine-based ligands: An overview of selected structural features
2017, Coordination Chemistry ReviewsCitation Excerpt :Inagaki et al. studied the products of the reactions of [PtCl2(R,R-dach)] with dApG, dGpA, dpGpA and rGpA, which were identified by UV and CD spectroscopy after the HPLC separation as [Pt(R,R-dach)(dApG)-N1(1)N7(2)], [Pt(R,R-dach)(dApG)-N7(1)N7(2)], [Pt(R,R-dach)(dGpA)-N7(1)N1(2)], [Pt(R,R-dach)(dGpA)-N7(1)N7(2)], [Pt(R,R-dach)(dpGpA)-N7(1)N1(2)], [Pt(R,R-dach)(dpGpA)-N7(1)N7(2)], [Pt(R,R-dach)r(GpA)-N7(1)N1(2)] and [Pt(R,R-dach)r(GpA)-N7(1)N7(2)] [173]. The mentioned complex [Pt(R,R-dach)(dApG)-N7(1)N7(2)] [22,173–175] and its analogs involving other dach isomers {[Pt(R,S-dach)(dApG)-N7(1)N7(2)] and [Pt(S,S-dach)(dApG)-N7(1)N7(2)] [176]} and derivatives {[Pt(R,S,S-medach)(dApG)-N7(1)N7(2)] [177]} were also studied and described in the literature (medach = 3-methyl-1,2-diaminocyclohexane). The reaction of trans-[PtCl2(NH3)2] with DNA and enzymatic digestion of the product led to substances with compositions that were identified by NMR as [PtCl2(dCpT)-N3(2)-(dApG)-N1(1)], [PtCl2(dguo-N7)(dApT)-N1(1)], [PtCl2(dguo-N7)(dApC)-N1(1)], [PtCl2(dguo-N7)(dCpA)-N3(1)], [PtCl2(dguo-N7)(dApA)-N1(1)], and [PtCl2(dguo-N7)(dApG)-N1(1)] [43].
New binary and ternary platinum(II) formamidine complexes: Synthesis, characterization, structural studies and in-vitro antitumor activity
2016, Journal of Molecular StructureCitation Excerpt :It contains diaminocyclohexane (carrier ligand) and oxalate (hydrolyzable ligand). It crosslinks at the nucleophilic sites on DNA of tumor cells [14,15] and inhibits RNA synthesis [16] thus inducing tumor cell death. Oxaliplatin has a broad spectrum of anti-tumor activity unlike cisplatin and carboplatin [17].
Effect of chirality in platinum drugs
2015, Coordination Chemistry Reviews